{"protocolSection": {"identificationModule": {"nctId": "NCT02943590", "orgStudyIdInfo": {"id": "16-440"}, "organization": {"fullName": "Massachusetts General Hospital", "class": "OTHER"}, "briefTitle": "STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)", "officialTitle": "STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)"}, "statusModule": {"statusVerifiedDate": "2023-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-01-13", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-09-16", "type": "ACTUAL"}, "completionDateStruct": {"date": "2023-10-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-10-21", "studyFirstSubmitQcDate": "2016-10-21", "studyFirstPostDateStruct": {"date": "2016-10-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2023-10-18", "resultsFirstSubmitQcDate": "2023-11-29", "resultsFirstPostDateStruct": {"date": "2023-12-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-11-29", "lastUpdatePostDateStruct": {"date": "2023-12-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Tomas G. Neilan, MD", "investigatorTitle": "MD", "investigatorAffiliation": "Massachusetts General Hospital"}, "leadSponsor": {"name": "Massachusetts General Hospital", "class": "OTHER"}, "collaborators": [{"name": "Dana-Farber Cancer Institute", "class": "OTHER"}, {"name": "Brigham and Women's Hospital", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin is from a family of medications that are commonly called \"statins\"", "detailedDescription": "This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of a drug and determine whether the investigational drug works in treating a specific disease. \"Investigational\" means that the drug is being studied.\n\nThe chemotherapy drug that the participant have been scheduled to be treated with, Doxorubicin, has been associated with the development of heart failure in some patients.\n\nThis research study is testing whether Atorvastatin can protect the hearts of patients being treated with Doxorubicin and can reduce cardiac injury and the risk of heart failure. Atorvastatin is not approved by the FDA (the U.S. Food and Drug Administration) for use to reduce the cardiac injury after Doxorubicin. Atorvastatin is approved by the FDA for lowering cholesterol and for reducing the risk of heart attack and stroke. The heart is a muscle that pumps blood and Atorvastatin may protect the heart by preserving cardiac muscle function.\n\nThe investigators will test whether atorvastatin protects the heart using a combination of imaging tests on the participants heart, blood tests, and stress testing. The imaging tests will involve an echocardiogram (an echo) and cardiac magnetic resonance (CMR), a type of magnetic resonance imaging (MRI) scan."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Cancer Treatment Related to Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 300, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)", "interventionNames": ["Drug: Placebo"]}, {"label": "Atorvastatin", "type": "EXPERIMENTAL", "description": "Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)", "interventionNames": ["Drug: Atorvastatin"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "description": "A pill taken once a day", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Atorvastatin", "description": "A pill taken once a day", "armGroupLabels": ["Atorvastatin"], "otherNames": ["Lipitor"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Percentage of Individuals in Each Group With a Significant Decline in the LVEF.", "description": "To determine if the administration of statins is associated with a lower percentage of individuals who experience a significant decline in the LVEF at 12 months. The primary outcome was the percentage of participants with an absolute decline in left ventricular ejection fraction (LVEF) of\\>10% from prior to chemotherapy to a final value of \\<55% over 12 months.", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "The Percentage of Participants in Each Group With New Onset Heart Failure.", "description": "To determine whether statins reduce the percentage of participants in each group with new onset heart failure after anthracyclines.", "timeFrame": "2 years"}, {"measure": "Myocardial Extracellular Volume by Cardiac MRI.", "description": "To determine if anthracyclines lead to an increase in myocardial fibrosis, myocardial extracellular volume, as measured by cardiac MRI and whether statins attenuate the increase in myocardial fibrosis.", "timeFrame": "1 Year"}, {"measure": "Global Longitudinal Strain", "description": "To determine whether anthracyclines lead to a reduction in global longitudinal strain (GLS), whether the reduction in GLS associates with the decline in LVEF and whether statins attenuate the anthracycline-associated reduction in GLS.", "timeFrame": "1 Year"}, {"measure": "Troponin", "description": "To determine if anthracyclines lead to an increase in serum troponin, to determine if the increase in serum troponin related to the decline in cardiac function and whether statins attenuate the increase in serum troponin.", "timeFrame": "1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* \\> 18 years of age\n* All patients with newly diagnosed NHL and HL\n* Scheduled to receive anthracycline-based therapy\n\nExclusion Criteria:\n\n* Statin use or Statin use is indicated based on guidelines\n* Pregnancy or breastfeeding\n* Unable to provide informed consent\n* Unexplained persistent elevation of transaminases (\\>3 times upper limits of normal)\n* Concomitant use of cyclosporine\n* Renal failure: estimated glomerular filtration \\<45 mL/min/1.73 m2\n* Contraindication to a CMR (metallic object, severe claustrophobia, pacemaker, vascular clip\n* LVEF of \\<50% at baseline", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Tomas G Neilan, MD", "affiliation": "Massachusetts General Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Massachusetts general Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02114", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Dana Farber Cancer Institute", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "University of Pennsylvania Medical System", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "McGill University Health Center", "city": "Toronto", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "1:1 randomization", "groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)\n\nPlacebo: A pill taken once a day"}, {"id": "FG001", "title": "Atorvastatin", "description": "Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)\n\nAtorvastatin: A pill taken once a day"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "150"}, {"groupId": "FG001", "numSubjects": "150"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "144"}, {"groupId": "FG001", "numSubjects": "142"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo group"}, {"id": "BG001", "title": "Atorvastatin", "description": "Atorvastatin group"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "150"}, {"groupId": "BG001", "value": "150"}, {"groupId": "BG002", "value": "300"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "130"}, {"groupId": "BG001", "value": "130"}, {"groupId": "BG002", "value": "260"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "40"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "49", "spread": "16"}, {"groupId": "BG001", "value": "50", "spread": "17"}, {"groupId": "BG002", "value": "50", "spread": "16"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "74"}, {"groupId": "BG001", "value": "68"}, {"groupId": "BG002", "value": "142"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "82"}, {"groupId": "BG002", "value": "158"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "11"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "9"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "131"}, {"groupId": "BG001", "value": "135"}, {"groupId": "BG002", "value": "266"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "14"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "20"}]}]}, {"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "140"}, {"groupId": "BG001", "value": "140"}, {"groupId": "BG002", "value": "280"}]}]}]}, {"title": "LVEF", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62.5", "spread": "4.9"}, {"groupId": "BG001", "value": "63", "spread": "4.5"}, {"groupId": "BG002", "value": "63", "spread": "4.6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Percentage of Individuals in Each Group With a Significant Decline in the LVEF.", "description": "To determine if the administration of statins is associated with a lower percentage of individuals who experience a significant decline in the LVEF at 12 months. The primary outcome was the percentage of participants with an absolute decline in left ventricular ejection fraction (LVEF) of\\>10% from prior to chemotherapy to a final value of \\<55% over 12 months.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)\n\nPlacebo: A pill taken once a day"}, {"id": "OG001", "title": "Atorvastatin", "description": "Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)\n\nAtorvastatin: A pill taken once a day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "142"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "9"}]}]}]}, {"type": "SECONDARY", "title": "The Percentage of Participants in Each Group With New Onset Heart Failure.", "description": "To determine whether statins reduce the percentage of participants in each group with new onset heart failure after anthracyclines.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "2 years", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)\n\nPlacebo: A pill taken once a day"}, {"id": "OG001", "title": "Atorvastatin", "description": "Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)\n\nAtorvastatin: A pill taken once a day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "142"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Myocardial Extracellular Volume by Cardiac MRI.", "description": "To determine if anthracyclines lead to an increase in myocardial fibrosis, myocardial extracellular volume, as measured by cardiac MRI and whether statins attenuate the increase in myocardial fibrosis.", "reportingStatus": "NOT_POSTED", "anticipatedPostingDate": "2024-10", "timeFrame": "1 Year", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Global Longitudinal Strain", "description": "To determine whether anthracyclines lead to a reduction in global longitudinal strain (GLS), whether the reduction in GLS associates with the decline in LVEF and whether statins attenuate the anthracycline-associated reduction in GLS.", "reportingStatus": "NOT_POSTED", "anticipatedPostingDate": "2024-10", "timeFrame": "1 Year", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Troponin", "description": "To determine if anthracyclines lead to an increase in serum troponin, to determine if the increase in serum troponin related to the decline in cardiac function and whether statins attenuate the increase in serum troponin.", "reportingStatus": "NOT_POSTED", "anticipatedPostingDate": "2024-10", "timeFrame": "1 year", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "12 months", "description": "No difference", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)\n\nPlacebo: A pill taken once a day", "deathsNumAffected": 4, "deathsNumAtRisk": 150, "seriousNumAffected": 0, "seriousNumAtRisk": 150, "otherNumAffected": 21, "otherNumAtRisk": 150}, {"id": "EG001", "title": "Atorvastatin", "description": "Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)\n\nAtorvastatin: A pill taken once a day", "deathsNumAffected": 4, "deathsNumAtRisk": 150, "seriousNumAffected": 0, "seriousNumAtRisk": 150, "otherNumAffected": 28, "otherNumAtRisk": 150}], "otherEvents": [{"term": "Muscle pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 150}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 150}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Tomas Neilan", "organization": "MassGH", "email": "tneilan@partners.org", "phone": "617726200"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-02-02", "uploadDate": "2023-10-18T10:06", "filename": "Prot_000.pdf", "size": 2296638}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2022-06-07", "uploadDate": "2023-10-18T10:05", "filename": "SAP_001.pdf", "size": 200606}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2022-04-01", "uploadDate": "2023-11-29T10:26", "filename": "ICF_002.pdf", "size": 484163}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000066126", "term": "Cardiotoxicity"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000064420", "term": "Drug-Related Side Effects and Adverse Reactions"}, {"id": "D000064419", "term": "Chemically-Induced Disorders"}, {"id": "D000011832", "term": "Radiation Injuries"}, {"id": "D000014947", "term": "Wounds and Injuries"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M30670", "name": "Cardiotoxicity", "asFound": "Cardiotoxicity", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M30303", "name": "Drug-Related Side Effects and Adverse Reactions", "relevance": "LOW"}, {"id": "M30302", "name": "Chemically-Induced Disorders", "relevance": "LOW"}, {"id": "M14679", "name": "Radiation Injuries", "relevance": "LOW"}, {"id": "M17685", "name": "Wounds and Injuries", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC25", "name": "Substance Related Disorders"}, {"abbrev": "BC26", "name": "Wounds and Injuries"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069059", "term": "Atorvastatin"}], "ancestors": [{"id": "D000000924", "term": "Anticholesteremic Agents"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}, {"id": "D000019161", "term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M351", "name": "Atorvastatin", "asFound": "General", "relevance": "HIGH"}, {"id": "M21155", "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "relevance": "LOW"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Lipd", "name": "Lipid Regulating Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}